APVO436 + azacitidine

APVO436 + azacitidine is an investigational combination therapy comprising APVO436, a recombinant humanized bispecific antibody targeting CD3 (on T-cells) and CD123 (on leukemia cells), and azacitidine, a hypomethylating agent that blocks the growth of cancer cells. APVO436 redirects host T-cells toward CD123-expressing acute myeloid leukemia (AML) cells, facilitating immunologic killing. The combination is being developed for the treatment of patients with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML), particularly in cases with poor prognostic features or resistance to other regimens. Clinical trials have evaluated the combination with or without venetoclax, with results suggesting favorable efficacy and manageable safety in AML. APVO436 is developed by Aptevo Therapeutics, and azacitidine is a generic small molecule marketed by several companies. The regimen is under clinical investigation and is not FDA approved.[1][2][3][4][5]